X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (842) 842
Publication (64) 64
Book Review (16) 16
Book Chapter (4) 4
Newsletter (4) 4
Conference Proceeding (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (556) 556
index medicus (505) 505
female (399) 399
osteoprotegerin (369) 369
male (345) 345
middle aged (300) 300
aged (218) 218
osteoprotegerin - blood (210) 210
osteoporosis (209) 209
adult (207) 207
serum osteoprotegerin (197) 197
endocrinology & metabolism (193) 193
receptor activator (150) 150
animals (147) 147
biomarkers - blood (145) 145
risk factors (136) 136
postmenopausal women (133) 133
inflammation (123) 123
serum-levels (123) 123
kappa-b ligand (122) 122
serum (119) 119
research (116) 116
expression (111) 111
atherosclerosis (109) 109
bone (108) 108
rankl (104) 104
mineral density (103) 103
bone density (101) 101
biomarkers (100) 100
vascular calcification (96) 96
metabolism (94) 94
rheumatology (94) 94
musculoskeletal diseases (93) 93
research article (93) 93
disease (92) 92
serum levels (90) 90
bone-mineral density (88) 88
medicine (88) 88
analysis (85) 85
physiological aspects (85) 85
opg (83) 83
cytokines (82) 82
case-control studies (81) 81
care and treatment (80) 80
bones (79) 79
calcification (79) 79
bone mineral density (76) 76
rank ligand - blood (74) 74
bone turnover (73) 73
medicine, research & experimental (73) 73
biocompatibility (72) 72
bone and bones - metabolism (72) 72
serum osteoprotegerin levels (71) 71
health aspects (70) 70
coronary-artery-disease (69) 69
density (69) 69
osteoprotegerin - metabolism (68) 68
aged, 80 and over (67) 67
enzyme-linked immunosorbent assay (65) 65
mice (64) 64
mortality (64) 64
trance protein (64) 64
diabetes (62) 62
proteins (59) 59
immunology (58) 58
rank ligand - metabolism (58) 58
studies (57) 57
bone resorption (56) 56
cells (56) 56
cross-sectional studies (56) 56
osteoclastogenesis (56) 56
risk (56) 56
women (56) 56
c-reactive protein (55) 55
cardiovascular-disease (55) 55
osteoclast differentiation (54) 54
rheumatoid arthritis (54) 54
gene expression (53) 53
oncology (53) 53
rank ligand (53) 53
genetic aspects (52) 52
tumor necrosis factor-tnf (52) 52
biochemical markers (51) 51
biomedical materials (50) 50
ligands (50) 50
medical research (50) 50
multidisciplinary sciences (50) 50
patients (50) 50
urology & nephrology (50) 50
arthritis (49) 49
biochemistry & molecular biology (49) 49
cell biology (49) 49
medicine & public health (47) 47
prognosis (47) 47
review (47) 47
science (47) 47
cardiovascular disease (46) 46
orthopedics (45) 45
biology (44) 44
rats (44) 44
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Bone, ISSN 8756-3282, 10/2019, Volume 127, pp. 215 - 219
There have been new advances in understanding bone remodeling on a molecular level including the RANKL-OPG pathway, leading to advancements in targeted... 
Pediatric osteoporosis | Puberty | Obesity | RANK ligand | OPG | SERUM OSTEOPROTEGERIN | TURNOVER | BONE-MINERAL DENSITY | BIOCHEMICAL MARKERS | DENOSUMAB | ALENDRONATE | HORMONE | ENDOCRINOLOGY & METABOLISM | RECEPTOR ACTIVATOR | POSTMENOPAUSAL WOMEN | OBESE | Chronic diseases | Osteoporosis | Children | Pediatric clinics | Analysis
Journal Article
Hormone and Metabolic Research, ISSN 0018-5043, 07/2018, Volume 50, Issue 7, pp. 562 - 567
Abstract The objective of this study was to investigate the effect of hyperprolactinemia and high levels of insulin-like growth factor-I (IGF-I) on bone... 
Endocrine Care | insulin-like growth factor-I | RANKL | bone | prolactinoma | osteoprotegerin | IGF-I | LIGAND/OSTEOPROTEGERIN | TURNOVER | HORMONE | METABOLISM | SERUM-LEVELS | ENDOCRINOLOGY & METABOLISM | RECEPTOR ACTIVATOR | KAPPA-B LIGAND | GROWTH-FACTOR-I
Journal Article
Annals of the Rheumatic Diseases, ISSN 0003-4967, 06/2018, Volume 77, Issue Suppl 2, p. 1019
BackgroundWe have previously found that IL-18 and OPG serum concentrations are correlated with cardiovascular (CV) risk in psoriatic arthritis but not in... 
Lipoproteins (low density) | Statistical analysis | Cytokines | Cardiovascular disease | Lipids | Arthritis | Triglycerides | Coronary artery disease | Cholesterol | Interleukin 18 | Osteoprotegerin | Serum levels | Spondylitis | Interleukin 1 | Cardiovascular diseases | Lipoproteins (high density) | Heart diseases | Ankylosing spondylitis
Journal Article
Anticancer Research, ISSN 0250-7005, 08/2018, Volume 38, Issue 8, p. 4907
Background/Aim: Melanoma represents one of the most aggressive forms of cancer. With the rapid increases in the incidence of melanoma in the United States,... 
Epidemics | Statistical analysis | Melanoma | Osteopontin | Patients | Subgroups | Metastases | Skin cancer | Osteoprotegerin | Serum levels | Biomedical materials | Epidermal growth factor | Biomarkers | Biocompatibility | Bioindicators | Vascular endothelial growth factor | Growth factors | Significance | Cancer
Journal Article
Heart and Vessels, ISSN 0910-8327, 11/2017, Volume 32, Issue 11, pp. 1304 - 1313
Osteoprotegerin (OPG) and receptor activator of nuclear factor-κB ligand (RANKL) are regulators of bone remodeling, but are also considered to play important... 
Biomedical Engineering | Medicine & Public Health | Cardiac Surgery | Cytokines | Atherosclerosis | Receptor activator of nuclear factor-κB ligand (RANKL) | Vascular Surgery | Osteoprotegerin (OPG) | Inflammation | Cardiology | LONG-TERM PROGNOSIS | SERUM OSTEOPROTEGERIN | RANKL | CARDIAC & CARDIOVASCULAR SYSTEMS | VASCULAR CALCIFICATION | SYSTEMIC INFLAMMATION | GENERAL-POPULATION | ENDOTHELIAL-CELLS | SOLUBLE RECEPTOR ACTIVATOR | PERIPHERAL VASCULAR DISEASE | Receptor activator of nuclear factor-kappa B ligand (RANKL) | CORONARY-ARTERY-DISEASE | KAPPA-B LIGAND | Morbidity - trends | Enzyme-Linked Immunosorbent Assay | Risk Assessment | Humans | Middle Aged | Risk Factors | Male | Biomarkers - blood | Atherosclerosis - epidemiology | Coronary Artery Disease - blood | Germany - epidemiology | Atherosclerosis - blood | Young Adult | RANK Ligand - blood | Osteoprotegerin - blood | Aged, 80 and over | Adult | Female | Aged | Coronary Artery Disease - epidemiology | Cytokines - blood | Medical research | Enzymes | Medical colleges | Care and treatment | Biological response modifiers | Coronary heart disease | Risk factors | Interleukins | Cardiac patients | Medicine, Experimental | Interferon | Plasma | Regulators | Interleukin | Fluorescence | Cardiovascular disease | Osteoprotegerin | Interleukin 4 | Biomedical materials | IP-10 protein | Biocompatibility | TRANCE protein | Heart diseases | Bone remodelling | Coronary artery | Health risks | Interleukin 13 | Coronary artery disease | Patients | Correlation analysis | Arteriosclerosis | γ-Interferon | Plasma levels | Cardiovascular diseases | Laser applications | Monocyte chemoattractant protein 1 | Immunoassays | Plasmas (physics)
Journal Article
Journal of Dentistry, ISSN 0300-5712, 2012, Volume 40, Issue 5, pp. 364 - 371
Journal Article
CLINICAL BIOCHEMISTRY, ISSN 0009-9120, 06/2008, Volume 41, Issue 9, pp. 746 - 749
Objective: Evaluation of serum and synovial fluid OPG and sRANKL in 37 patients with primary knee osteoarthritis. Design and method: OPG and sRANKL were... 
RHEUMATOID-ARTHRITIS | OSTEOCLAST | knee osteoarthritis | synovial fluid | osteoprotegerin (OPG) | MEDICAL LABORATORY TECHNOLOGY | serum | EXPRESSION | receptor activator of nuclear factor-KB ligand (RANKL)
Journal Article
Journal Article
Scandinavian Journal of Clinical and Laboratory Investigation, ISSN 0036-5513, 2007, Volume 67, Issue 4, pp. 387 - 393
Journal Article
PLoS ONE, ISSN 1932-6203, 07/2015, Volume 10, Issue 7, p. e0133964
Background Breast cancer patients treated with aromatase inhibitors (AIs) may experience musculoskeletal adverse events (MS-AEs). Several studies have... 
LYS3ASN POLYMORPHISM | OSTEOPROTEGERIN OPG | FRACTURE | BONE-MINERAL DENSITY | ACUPUNCTURE | RANKL/RANK/OPG | MULTIDISCIPLINARY SCIENCES | TURNOVER MARKERS | POSTMENOPAUSAL WOMEN | EXPRESSION | ANASTROZOLE | Genetic Predisposition to Disease | Prognosis | Follow-Up Studies | Humans | Middle Aged | Asian Continental Ancestry Group - genetics | Genotype | Breast Neoplasms - drug therapy | Case-Control Studies | Musculoskeletal Diseases - genetics | RANK Ligand - genetics | Aromatase Inhibitors - adverse effects | Breast Neoplasms - genetics | Neoplasm Grading | Breast Neoplasms - pathology | Musculoskeletal Diseases - chemically induced | Osteoprotegerin - genetics | Polymerase Chain Reaction | Polymorphism, Single Nucleotide - genetics | Female | Care and treatment | Cancer patients | Cytokines | Analysis | Estrogen | Breast cancer | Genetic aspects | B cells | Single nucleotide polymorphisms | Chromosomes | Spine | Spine (lumbar) | Genes | Oncology | Risk | Genomes | Single-nucleotide polymorphism | Assaying | Cancer therapies | Synergism | Estradiol | Regulatory approval | Osteoprotegerin | Osteoporosis | Signal transduction | Pain | Aromatase | Bone density | TRANCE protein | Genotypes | Narcotics | Markers | Inflammation | Bone turnover | Patients | Carriers | Serum levels | Studies | Sex hormones | Signaling | Bone cancer | Hospitals | Womens health | Rheumatoid arthritis | Collagen | Breast | Bone mineral density | Hormone replacement therapy | Bone | Cancer
Journal Article